SEOUL, South Korea, May 24, 2024 /PRNewswire/ — On the 23rd, K-PET ( http://k-pet.fourdpocket.com/) announced the development of a new pet disease prevention solution, tentatively named K-PET, utilizing genetic analysis technology.

Despite the rapid growth of the domestic pet market, pets face significant challenges in disease prevention compared to humans, often resulting in shorter lifespans or abandonment. To tackle these issues, K-PET aims to support disease prevention and extend the healthy lifespans of pets through cancer and disease genetic testing.

The process for genetic disease testing involves remotely collecting cells from pets, followed by RT-PCR to detect genetic mutations and DNA profiling. Pet owners can then review the results and receive consultations through an app.

Furthermore, K-PET plans to offer a comprehensive one-stop service covering the entire lifecycle of pets. This includes providing information on nearby veterinary clinics, a shopping mall for supplements and pet food, insurance options, and funeral services.

Kim Hee-tae, CEO of K-PET, stated, "K-PET offers disease genetic information through PCR testing of pet DNA. By preventing potential diseases through remote genetic testing, we aim to contribute to not just the extension of lifespans but the extension of healthy lifespans for pets."

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Beyond Bank and Cognizant join forces to lead the future of customer-owned banking

Beyond Bank Australia leverages Cognizant’s expertise to modernize IT infrastructure and enhance…

AOFAR Officially Launches GX6: The Top Budget Rechargeable Golf Rangefinder for 2025

NEW YORK, June 28, 2025 /PRNewswire/ — AOFAR today announced the release…

First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)

INCHEON, South Korea, Feb. 8, 2024 /PRNewswire/ — Zymedi announced today that the…